SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001520138-21-000081
Filing Date
2021-01-29
Accepted
2021-01-29 17:02:06
Documents
51
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR PERIOD ENDING DECEMBER 31, 2020 bivi-20201231_10q.htm   iXBRL 10-Q 549336
2 EXHIBIT 31.1 bivi-20201231_10qex31z1.htm EX-31.1 12110
3 EXHIBIT 31.2 bivi-20201231_10qex31z2.htm EX-31.2 12225
4 EXHIBIT 32.1 bivi-20201231_10qex32z1.htm EX-32.1 5292
5 EXHIBIT 32.2 bivi-20201231_10qex32z2.htm EX-32.2 5135
  Complete submission text file 0001520138-21-000081.txt   3189593

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE bivi-20201231.xsd EX-101.SCH 28853
7 XBRL CALCULATION FILE bivi-20201231_cal.xml EX-101.CAL 33190
8 XBRL DEFINITION FILE bivi-20201231_def.xml EX-101.DEF 115162
9 XBRL LABEL FILE bivi-20201231_lab.xml EX-101.LAB 225290
10 XBRL PRESENTATION FILE bivi-20201231_pre.xml EX-101.PRE 200898
11 EXTRACTED XBRL INSTANCE DOCUMENT bivi-20201231_10q_htm.xml XML 461156
Mailing Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404
Business Address 2120 COLORADO AVE. SUITE 230 LOS ANGELES CA 90404 310-444-4300
BIOVIE INC. (Filer) CIK: 0001580149 (see all company filings)

IRS No.: 462510769 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 001-39015 | Film No.: 21572123
SIC: 2834 Pharmaceutical Preparations